| Date | Title | Description |
| 02.08.2023 | Aridis Pharmaceuticals Announces $2 Million Offering | - |
| 27.01.2022 | Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission | LOS GATOS, Calif., Jan. 27, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, recei... |
| 21.12.2021 | Aridis Pharmaceuticals : Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron - Form 8-K | Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal
Antibody Cocktail That Retains Effectiveness Against the Omicron
variant, other COVID-19 Variants, SARS, MERS, and the Common Cold
Human Coronaviruses
AR-701 cocktail binds to th... |
| 21.12.2021 | Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human C... | LOS GATOS, Calif., Dec. 21, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, annou... |
| 10.11.2021 | Aridis Pharmaceuticals Announces Third Quarter 2021 Results - Form 8-K | Aridis Pharmaceuticals Announces Third Quarter 2021 Results
Executed AstraZeneca in-licensing deal of Phase 3-ready antibody, suvratoxumab, in July 2021
Bolstered financial position with approx. $25 million in equity financing in August 202... |
| 12.08.2021 | Aridis Pharmaceuticals Announces Second Quarter 2021 Results | |
| 12.08.2021 | Aridis Pharmaceuticals : Confirmed that SARS-CoV-2 antibody combination AR-712 is active against the Delta variant and all other strains on the CDCs Variants of Interest and Variants of Concern lists ... | Confirmed that SARS-CoV-2 antibody combination AR-712 is active against the Delta variant and all other strains on the CDCs Variants of Interest and Variants of Concern lists
LOS GATOS, Calif., August 12, 2021 /PRNewswire/ -- Aridis Pharmac... |
| 04.08.2021 | Aridis Pharmaceuticals : Announces $25 Million Registered Direct Offering Priced At a Premium to Market (Form 8-K) | Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced At a Premium to Market
LOS GATOS, Calif., August 2, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the ... |
| 02.08.2021 | Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market | |
| 02.08.2021 | Aridis Pharmaceuticals : Announces $25 Million Registered Direct Offering Priced at a Premium to Market | LOS GATOS, Calif., Aug. 2, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today ... |
| 26.07.2021 | Aridis Pharmaceuticals : CoVIC's animal efficacy data shows that Aridis' AR-711 mAb is among the top 5 most potent out of more than 350 COVID mAbs that have entered the CoVIC evaluation program to dat... | CoVIC's animal efficacy data shows that Aridis' AR-711 mAb is among the top 5 most potent out of more than 350 COVID mAbs that have entered the CoVIC evaluation program to date
The dual mAbs cocktail AR-712 bind to the Delta and Delta Plus ... |
| 26.07.2021 | Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC) | |
| 20.07.2021 | Aridis Pharmaceuticals : Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca | LOS GATOS, Calif. - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to in-license the late stage monoclonal antibody candidate... |
| 19.07.2021 | Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca | |
| 19.07.2021 | Aridis Pharmaceuticals : Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca (Form 8-K) | Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab,
a Phase 3-Ready Monoclonal Antibody, from AstraZeneca
Los Gatos, Calif., July 19, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it h... |
| 13.07.2021 | Aridis Pharmaceuticals : Binding analysis projects the ability of AR-712 to bind to all variants on the Center for Disease Control's Variants of Interest and Variants of Concern lists (Form 8-K) | Binding analysis projects the ability of AR-712 to bind to all variants on the Center for Disease Control's Variants of Interest and Variants of Concern lists
LOS GATOS, Calif., July 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Na... |
| 12.07.2021 | Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant | |
| 12.07.2021 | Aridis Pharmaceuticals : COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant | LOS GATOS, Calif., July 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, annou... |
| 11.05.2021 | ARIDIS PHARMACEUTICALS, INC.
Aridis Pharmaceuticals : Announces First Quarter 2021 Results | LOS GATOS, Calif., May 11, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today ... |
| 31.03.2021 | ARIDIS PHARMACEUTICALS, INC.
Aridis Pharmaceuticals : Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update | LOS GATOS, Calif., March 30, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, toda... |
| 30.03.2021 | Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update | |
| 08.03.2021 | Aridis Enters into APEX™ Licensing and Product Discovery Agreement for Zoonotic Viruses with Kermode | |
| 23.02.2021 | Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants | |
| 20.11.2020 | Aridis Pharmaceuticals Announces Third Quarter 2020 Results | |
| 19.07.2018 | Aridis Pharma seeks $35M to fight infections with immunotherapies — latest in an IPO streak | Getting ready for its first Phase III trial, Aridis Pharma is now turning to public investors to support its pathogen-specific immunotherapies in a modest $35 million IPO.
Vu Truong
San Jose, CA-based Aridis joins an ever-grow... |
| 06.06.2013 | Kenta Biotech sells Monoclonal Antibody Products and Technologies to Aridis | |
| 07.03.2008 | Life-science briefing: Friday, March 7, 2008 | TODAY’S HEADLINES:
Allegro pulls in $4M for lung-cancer molecular diagnostics (release)
Ocular bandage developer I-Therapeutix raises $6M (Mass High Tech)
NanoBio gets last of $30M for skin-infection drugs (release)
Cayenne Medical raises $... |
